Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 4/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27426825 | 1.00 | SLC1A1 (0.49) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL27543988 | 0.88 | SLC1A1 (0.44) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL27533978 | 0.85 | ALDH1A1 (0.47) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL8257115 | 0.85 | ALDH1A1 (0.47) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL12873771 | 0.84 | KMT2A (0.49) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL2528757 | 0.84 | IDO1 (0.46) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL14517178 | 0.84 | KMT2A (0.49) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL27697735 | 0.84 | IDO1 (0.46) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL24535009 | 0.83 | ALDH1A1 (0.52) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL6649720 | 0.81 | LMNA (0.55) | KMT2AALDH1A1IDO1HCAR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058840-A | 2-Asn-tetrahydroisoquinoline-3S-formyl-Ala, and preparation and application thereof | 首都医科大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-120058839-A | 2-Asn-tetrahydroisoquinoline-3S-formyl-Leu, and preparation and application thereof | 首都医科大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-117510578-B | TNF-alpha inhibitor 2-Asn-tetrahydroisoquinoline-3S-formyl-AA, preparation and application | 首都医科大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-117567552-B | Four 2-Thr-tetrahydroisoquinoline-3S-formyl-AA compounds of IL-2 agonist, preparation and application | 首都医科大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-117567553-B | 2-Thr-dihydroisoquinoline-3S-formyl-AA as IL-2 agonist, and preparation and antitumor application thereof | 首都医科大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-117510575-B | 2-Gly-tetrahydroisoquinoline-3S-formyl-AA compound of IL-10 agonist, and preparation and application thereof | 首都医科大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-117946205-A | 2-Gly-dihydroisoquinoline-3S-formyl-AA of IL-10 agonist, preparation and antitumor application | 首都医科大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-115477656-B | Dioxahexacyclic-tetrahydrocarboline-3-formylamino acid targeting P-selectin, preparation and application | 首都医科大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-117720616-A | IL-8 agonist 2-Trp-dihydroisoquinoline-3S-formyl-AA, and preparation and antitumor application thereof | 首都医科大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-117567553-A | 2-Thr-dihydroisoquinoline-3S-formyl-AA as IL-2 agonist, and preparation and antitumor application thereof | 首都医科大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-117567552-A | Four 2-Thr-tetrahydroisoquinoline-3S-formyl-AA compounds of IL-2 agonist, preparation and application | 首都医科大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-117510579-A | 2-Trp-tetrahydroisoquinoline-3S-formyl-AA of IL-8 agonist and preparation and application thereof | 首都医科大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-117510575-A | 2-Gly-tetrahydroisoquinoline-3S-formyl-AA compound of IL-10 agonist, and preparation and application thereof | 首都医科大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-117510577-A | 2-Asn-dihydroisoquinoline-3S-formyl-AA of TNF-alpha agonist, preparation and anti-tumor application | 首都医科大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-117510578-A | TNF-alpha inhibitor 2-Asn-tetrahydroisoquinoline-3S-formyl-AA, preparation and application | 首都医科大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-115477656-A | Dioxane-tetrahydro carboline-3-formylamino acid with P-selectin as target and preparation and application thereof | 首都医科大学 | 2022-12-16 | — | — | CN | disclosed |
| US-20210252161-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | disclosed |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20190262463-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma AG (DE) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | SLC1A1 1596/4885SLC1A3 1047/4885SLC1A2 1881/4885 |
| US-20190262463-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | KIF5B, KIF15, KIF2C | SLC1A1 2804/4885SLC1A3 2798/4885SLC1A2 3137/4885 |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | SLC1A1 2804/4885SLC1A3 2798/4885SLC1A2 3137/4885 |
| US-20210252161-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | KIF5B, KIF15, KIF2C | SLC1A1 2804/4885SLC1A3 2798/4885SLC1A2 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.